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Ependymoma represents a heterogeneous disease affecting the en-
tire neuraxis. Extensive molecular profiling efforts have identified mo-
lecular ependymoma subgroups based on DNA methylation. However, the 
intratumoral heterogeneity and developmental origins of these groups are 
only partially understood, and effective treatments are still lacking for about 
50% of patients with high-risk tumors. We interrogated the cellular architec-
ture of ependymoma using single cell/nucleus RNA-sequencing to analyze 24 
tumor specimens across major molecular subgroups and anatomic locations. 
We additionally analyzed ten patient-derived ependymoma cell models and 
two patient-derived xenografts (PDXs). Interestingly, we identified an analo-
gous cellular hierarchy across all ependymoma groups, originating from 
undifferentiated neural stem cell-like populations towards different degrees 
of impaired differentiation states comprising neuronal precursor-like, astro-
glial-like, and ependymal-like tumor cells. While prognostically favorable 
ependymoma groups predominantly harbored differentiated cell popula-
tions, aggressive groups were enriched for undifferentiated subpopulations. 
Projection of transcriptomic signatures onto an independent bulk RNA-
seq cohort stratified patient survival even within known molecular groups, 
thus refining the prognostic power of DNA methylation-based profiling. 
Furthermore, we identified novel potentially druggable targets including 
IGF- and FGF-signaling within poorly prognostic transcriptional programs. 
Ependymoma-derived cell models/PDXs widely recapitulated the transcrip-
tional programs identified within fresh tumors and are leveraged to validate 
identified target genes in functional follow-up analyses. Taken together, 
our analyses reveal a developmental hierarchy and transcriptomic context 
underlying the biologically and clinically distinct behavior of ependymoma 
groups. The newly characterized cellular states and underlying regulatory 
networks could serve as basis for future therapeutic target identification and 
reveal biomarkers for clinical trials.
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We have previously shown immune gene phenotype variations between 
posterior fossa ependymoma subgroups. PFA1 tumors chronically secrete 
IL-6, which pushes the infiltrating myeloid cells to an immune suppressive 
function. In contrast, PFA2 tumors have a more immune activated pheno-
type and have a better prognosis. The objective of this study was to use 
single-cell(sc) RNAseq to descriptively characterize the infiltrating myeloid 
cells. We analyzed approximately 8500 cells from 21 PFA patient samples 
and used advanced machine learning techniques to identify distinct myeloid 
and lymphoid subpopulations. The myeloid compartment was difficult to 
interrupt as the data shows a continuum of gene expression profiles exist 
within PFA1 and PFA2. Through lineage tracing, we were able to tease 
out that PFA2 myeloid cells expressed more genes associated with an anti-
viral response (MHC II, TNF-a, interferon-gamma signaling); while PFA1 
myeloid cells had genes associated with an immune suppressive phenotype 
(angiogenesis, wound healing, IL-10). Specifically, we found expression of 
IKZF1 was upregulated in PFA2 myeloid cells. IKZF1 regulates differenti-
ation of myeloid cells toward M1 or M2 phenotype through upregulation 
of either IRF5 or IRF4 respectively. IRF5 expression correlated with IKZF1, 
being predominately expressed in the PFA2 myeloid cell subset. IKZF1 is 
also involved in T-cell activation. While we have not completed our charac-
terization of the T-cell subpopulation, we did find significantly more T-cell 
infiltration in PFA2 than PFA1. Moving forward these studies will provide 
us with valuable information regarding the molecular switches involved in 
the tumor-immune microenvironment and to better develop immunotherapy 
for PFA ependymoma.
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Ependymoma is the third commonest childhood brain tumour. Relapse 
is frequent, often fatal and current therapeutic strategies are inadequate. 
Previous ependymoma research describes an immunosuppressive envir-
onment with T-cell exhaustion, indicating a lack of response to T-cell dir-
ected immunotherapy. Understanding the immune microenvironment is 
therefore critical. We present a computational analysis of ependymoma, 
gene expression derived, immune profiles. Using 465 ependymoma sam-
ples from gene expression datasets (GSE64415, GSE50385, GSE100240) 
and two RNA-seq databases from UK ependymomas, we applied bulk tu-
mour deconvolution methods (CIBERSORT and xCell) to infer immune 
cell populations. Additionally, we measured checkpoint blockade related 
mRNAs and used immunohistochemistry to investigate cell populations in 
ependymoma sections. CIBERSORT indicated high proportions of M2-like 
macrophages and smaller proportions of activated natural killer (NK) cells, 
T follicular helper cells, CD4+ memory T-cells and B-cells. xCell overlapped 
with the M2-like macrophage and CD4+ memory T-cell signatures seen in 
CIBERSORT. On immunohistochemistry, T and B cells were scarce, with 
small numbers of CD8+, CD4+ and CD20+ cells in the parenchyma but 
greater numbers in surrounding regions. CD68 was more highly expressed 
in the parenchyma. Analysis of nine checkpoint ligands and receptors dem-
onstrated only the TIM3/GAL9 combination was reliably detectable. GAL9 
is implicated in tumour interactions with T-cells and macrophages else-
where, possibly contributing to poorer outcomes. Our study supports the 
presence of myeloid cells being leading contributors to the ependymoma im-
mune microenvironment. Further work will delineate the extent of myeloid 
contribution to immunosuppression across molecular subtypes. Modulation 
of tumour immunity may contribute to better clinical outcomes.
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Paediatric Ependymoma is the second most common malignant brain tu-
mour of childhood with approximately 50% of cases recurring. It has been 
described as a “surgical” disease since patients who have undergone a gross 
total surgical resection (GTR) have a better prognosis than those who have 
a subtotal resection (STR). Analysis of the UKCCSG/SIOP 1992 04 clinical 
trial has shown that only 49% of cases had a GTR, with 5-year survival 
rates for STR of 22–47% and GTR of 67–80%. As part of the SIOP II 
Ependymoma trial the UK established a panel of experts in the treatment of 
Ependymoma from Neuro-oncology, Neuro-radiology and Neuro-surgery. 
Meeting weekly, cases are discussed to provide a consensus on radiological 
review, ensuring central pathological review, trial stratification and whether 
further surgery should be advocated on any particular case. Evaluation of 
the first 68 UK patients has shown a GTR in 47/68 (69%) of patients and 
STR in 21/68 (31%) of patients. Following discussion at EMAG it was felt 
that 9/21 (43%) STR patients could be offered early second look surgery. 
Following this 2nd look surgery the number of cases with a GTR increased 
to 56/68 (82%). There has been a clear increase in the number of patients 
for whom a GTR has been achieved following discussion at EMAG and 
prior to them moving forwards with their oncological treatment. This can 
only have beneficial effects in decreasing their risk of tumour recurrence or 
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